Zonagen is a fraud and a scam
This is from the new Asensio report. From the looks of it, it is certainly filled with more research and intelligent commentary than the worthless crap you've been spewing about this fraud.
I believe that the recent surge in Zonagen's price is nothing more than interim short covering or new baseless speculation. I still maintain that this stock will soon fall to the floor and any moves upwards should be used as shorting opportunities.
-----------------------------
January 13, 1998
Zonagen's Vasomax patent application exposed.
Zonagen, Inc. (OTC Symbol: ZONA) has not disclosed the contents of the
Vasomax formulation included its pending U.S. patent application. The
patent application is not publicly available. However, on April 26, 1996
Zonagen also filed a Vasomax patent International Application under the
Patent Cooperation Treaty ("PCT") with the World Intellectual Property
Organization's International Bureau. The PCT application reveals Vasomax's
exact contents and formulation. We have obtained and reviewed a copy of
this application, which was published on October 31, 1996 under
International Publication Number WO 96/33705.
Zonagen claims that its Vasomax patent application contains legitimate
discovery claims and refers to Vasomax as a "new orally administered
formulation of phentolamine" and also as a "novel oral formulation."
However, Zonagen's PCT patent application proves that Vasomax's secret
formulation is merely and simply nothing more than plain 45 year old,
generic phentolamine. Vasomax contains no other active ingredients or any
other ingredients that alters phentolamine's chemistry or its effects on the
circulatory system.
Vasomax contains phentolamine and five other ingredients. All of these
other ingredients are completely inert and inactive. In fact, three of these
five non-active ingredients, which have no therapeutic value, are the same
ingredients, in the exact same quantities, as those found in what Zonagen
itself calls a "Standard Release" phentolamine tablet. All of the ingredients
in both the Vasomax and the Standard pills are commodity chemicals.
The two Vasomax ingredients that are different from the Standard pill are
an inert, bulking filler and an inert disintegrant. The inert, bulking filler in
Vasomax is lactose (a milk sugar). The Standard pill uses 228 mg of
dicalcium phosphate as its inert filler and does not contain a disintegrant.
Vasomax uses 212 mg of lactose. This slightly smaller quantity of lactose
filler allows the incorporation of 16 mg of croscarmellose sodium as a
disintegrant. A disintegrant aids in the physical disintegration and
dissolution of the pill by swelling after it is swallowed. The mere addition
of this simple common compound is the basis of Zonagen's formulation
discovery claims.
All of the ingredients in Zonagen's so-called "novel oral formulations" are
currently available to doctors and their patients. Any doctor can prescribe a
phentolamine pill with the same bulking and disintegrant ingredients mixed
in the same quantities if desired. Any compounding pharmacy can then
press the pill and dispense it to the patient for treatment of male erectile
dysfunction ("MED").
Zonagen's SEC filings acknowledge that prior oral phentolamine
formulations "have limited utility in treating erectile dysfunction." Vasomax
is a very simple formulation of phentolamine. In 1988 a study conducted in
West Germany was published in the Journal of Urology which showed that
phentolamine is not an effective MED treatment when injected directly into
the penis. Phentolamine acts on the local receptors in the circulatory
system. A phentolamine intracavenous injection into the penis acts on the
local circulatory system before other parts of the system without the
stomach losses and other dilution disadvantages of swallowing a pill.
Furthermore, an injection delivers the drug more quickly and with higher
plasma concentrations than any possible oral formulation. It is impossible
for any oral phentolamine pill, including the Vasomax formulation, to be a
more effective delivery system for MED treatment than an intracavenous
injection. |
